- Home
- / Erasca
Erasca
Stock Price
$2.8
2024-10-29
Market Capitalization
$791 M
2024-10-29
Erasca Summary
Company Summary
- Overview
- Erasca is a clinical-stage precision oncology company that discovers, develops, and commercializes therapies for cancer patients. It offers upstream and downstream mitogen-activated protein kinase (MAPK) pathway nodes with single agents and combinations; RAS, the midstream MAPK pathway node; and RAS/MAPK pathway-driven solutions.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- San Diego, CA, US | view all locations
- Website
- https://www.erasca.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
David Chacko, Chief Financial Officer and Chief Business Officer
Nik Chetwyn, Chief Operating Officer
Chandra Lovejoy, Chief Regulatory Affairs Officer
LocationsView all
1 location detected
San Diego, CA HQ
United States
3115 Merryfield Row Suite 300
Erasca Financials
Summary Financials
- Net income (Q1, 2026)
- ($183.4M)
- Cash (Q1, 2026)
- $47.3M
- EBIT (Q1, 2026)
- ($187.9M)
- Enterprise value
- $789.7M